Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.45 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5594422 | 0.82 | MAPT (0.46) | MEN1KMT2APTGS2LMNAQRFPR | |
| SCHEMBL5593964 | 0.82 | MEN1 (0.61) | MEN1KMT2APTGS2GRIN2B | |
| SCHEMBL5594283 | 0.81 | ADRA2A (0.46) | MEN1KMT2APTGS2LMNAPTGS1 | |
| SCHEMBL455629 | 0.79 | KMT2A (0.66) | MEN1KMT2AKDM4ELMNAF7 | |
| SCHEMBL4856204 | 0.78 | KMT2A (0.48) | MEN1KMT2AKDM4EPTGS2F7 | |
| SCHEMBL4854979 | 0.77 | PLAU (0.51) | MEN1KMT2AKDM4ELMNAF7 | |
| SCHEMBL4863537 | 0.77 | KMT2A (0.55) | KMT2AKDM4EQRFPRMAPTHTR3E | |
| SCHEMBL5594753 | 0.75 | P2RX7 (0.43) | PTGS2EGFRPTGS1GRIN2BALDH1A1 | |
| SCHEMBL27764447 | 0.75 | F7 (0.59) | MEN1KMT2AKDM4ELMNAF7 | |
| SCHEMBL834568 | 0.75 | F7 (0.59) | MEN1KMT2AKDM4ELMNAF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220770-B2 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2007-05-22 | — | — | US | disclosed |
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2005-11-17 | — | — | US | disclosed |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2005-05-05 | — | — | US | disclosed |
| US-6613789-B2 | Especially for treating arthritis, pain and fever | G. D. SEARLE & CO. | 2003-09-02 | — | — | US | disclosed |
| EP-0880504-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2003-02-20 | — | — | US | disclosed |
| EP-0772600-B1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1193265-A2 | A process for the preparation of 4-[2-(aryl or heterocyclo)-1H-imidazol-1-yl]benzenesulfonamides | G.D. Searle & Co. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | LTC4S, HRH4, LTB4R2 | MEN1 4754/4885KMT2A 2915/4885KDM4E 2382/4885 |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HCK, IL4I1, AHR | MEN1 4859/4885KMT2A 3035/4885KDM4E 2628/4885 |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HRH4, LTC4S, HCAR3 | MEN1 4787/4885KMT2A 3039/4885KDM4E 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.